Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2019

View Archived Issues

Buying time for therapy salvages lungs for transplant

Dynein axonemal heavy chain family identified as chemosensitivity-related genes in gastric cancer

Study confirms the oncogenic role of CDC20 in primary cutaneous squamous cell carcinoma

RPN2 as a biomarker to predict the outcome of chemotherapy for advanced gastric cancer

Small-molecule enhancers of E3 ligase-substrate interaction induce mutant beta-catenin degradation

A novel NOTCH3 mutation associated with epilepsy as an early manifestation of CADASIL

Surfactant protein D restricts HIV-1 passage across vaginal barrier in preclinical models

Tafazzin gene therapy created to treat Barth syndrome

InFlectis BioScience announces phase I results for IFB-088

Bispecific anti-VEGF/ANG-2 surrobody SL-634 shows potential to treat wet AMD

Vertex and Kymera enter strategic research and development collaboration

GABA-selective AAV therapy upregulates SCN1A to treat Dravet syndrome

New stroke therapy promotes motor recovery in mice

Bayer describes new P2X purinoceptor 3 antagonists

FORMA Therapeutics discloses new HDAC6 inhibitors

New phase I trial studies MK-8558 in antiretroviral-naive patients with HIV-1

FDA approves Venclexta with Gazyva for previously untreated CLL or SLL

FDA clears IND for Turning Point's TPX-0022

Emory University synthesizes fusion peptides including uPA or EGFR sequences with a toxin

Phase I/II results of DNase eye drops for dry eye disease

Vernalis, Servier present Bcl-2 inhibitors

New TrpC6 antagonists discovered by Hydra Biosciences and Boehringer Ingelheim

NCI studies whether Lixte's LB-100 can penetrate glioblastoma multiforme tumors

M.D. Anderson studies anti-PR1/HLA-A2 monoclonal antibody Hu8F4 in advanced hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Unnatural Products joins Argenx in a $1.5B macrocyclic deal
BioWorld
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
CMS eyes competitive bidding for CGMs, insulin pumps
BioWorld MedTech
The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...